DXCM logo

DexCom Inc. (DXCM)

$79.41

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on DXCM

Market cap

$29.62B

EPS

2.54

P/E ratio

33.3

Price to sales

6.39

Dividend yield

--

Beta

1.454458

Price on DXCM

Previous close

$84.46

Today's open

$82.73

Day's range

$79.20 - $82.85

52 week range

$54.11 - $92.59

Profile about DXCM

CEO

Jacob S. Leach

Employees

11100

Headquarters

San Diego, CA

Exchange

Nasdaq Global Select

Shares outstanding

372950922

Issue type

Common Stock

DXCM industries and sectors

Healthcare

Medical Equipment & Supplies

News on DXCM

DexCom to Launch 15-Day G7 CGM System in Canada This November

DXCM's upcoming Canadian launch of the G7 15 Day CGM, offering longer sensor wear and improved convenience, could boost international growth and patient access.

news source

Zacks Investment Research • Nov 3, 2026

news preview

Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today launched A Letter to Diabetes in honor of National Diabetes Awareness Month and World Diabetes Day, creating a platform for people around the world to put into words everything they've wanted to say about their diabetes journey, from the heartfelt and humorous to the hopeful and unexpected.Throughout November, anyone touched by diabetes is invited to share their own letter to diabetes, includi.

news source

Business Wire • Nov 2, 2026

news preview

DexCom: Improving Patient Access Makes It A Long-Term Buy

DXCM's recurring sensor model synergizes nicely with wider diabetes access thanks to Medicare. In fact, broader Medicare coverage could expand their overall addressable market, as long as DXCM is able to execute on that expanded opportunity. Also, DXCM now offers longer-wear sensors, and they intend to increase their manufacturing scale. So, those factors combined could improve margins as well.

news source

Seeking Alpha • Nov 2, 2026

news preview

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise

DXCM shares rise as Q3 earnings and revenues beat estimates, margins expand and 2026 guidance improves, driven by strong U.S. demand and G7 15 Day adoption.

news source

Zacks Investment Research • Oct 30, 2026

news preview

Diabetes Wearable-Maker Handily Beats Earnings Views, Hikes Sales Guide

Diabetes wearables-maker Dexcom topped third-quarter earnings forecasts Thursday and reported in-line sales. Dexcom stock was little moved.

news source

Investors Business Daily • Oct 29, 2026

news preview

What DexCom (DXCM) Said on Its Q3 Earnings Call

DexCom NASDAQ: DXCM reported third-quarter 2026 revenue of $1.34 billion, up 11% from a year earlier on both a reported and organic basis, as U.S. growth, market-share gains and manufacturing improvements supported higher profitability.

news source

MarketBeat • Oct 29, 2026

news preview

DexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript

DexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Oct 30, 2026

news preview

Dexcom Reports Third Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Third Quarter 2026 Financial Results.

news source

Business Wire • Oct 29, 2026

news preview

DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates

DexCom (DXCM) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.61 per share a year ago.

news source

Zacks Investment Research • Oct 29, 2026

news preview

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November

BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes. Offering up to 15.5 days of wear,2 Dexcom G7 15 Day combines industry leading sensor duration with best-in-class accuracy,1 giving Canadians living with diabetes more time between sensor changes and.

news source

Business Wire • Oct 28, 2026

news preview

¹ Disclosures

Get started with M1

Invest in DexCom Inc.

Open an M1 investment account to buy and sell DexCom Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in DXCM on M1